Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BenQ Medical TechnologyROCO:4116 -0.38%80 Return-on-Tangible-Asset is 0.99% as of Mar. 2026, which is 71% below its 10-year median of 3.41. GuruFocus rates ROCO:4116 with a GF Score™ of 80/100 and a GF Value™ of NT$58.30 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 855 Medical Devices & Instruments companies, BenQ Medical Technology ranks better than 51.7% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. BenQ Medical Technology's annualizedNet Income for the quarter that ended in Mar. 2026 was NT$50 Mil. BenQ Medical Technology's average total tangible assets for the quarter that ended in Mar. 2026 was NT$5,092 Mil. Therefore, BenQ Medical Technology's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 0.99%.
The historical rank and industry rank for BenQ Medical Technology's Return-on-Tangible-Asset or its related term are showing as below:
ROCO:4116'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.38 Med: 3.41 Max: 5.8
Current: 1.38
During the past 13 years, BenQ Medical Technology's highest Return-on-Tangible-Asset was 5.80%. The lowest was 1.38%. And the median was 3.41%.
ROCO:4116's Return-on-Tangible-Asset is ranked better than 51.7% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.89
vs ROCO:4116: 1.38
BenQ Medical Technology (ROCO:4116) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
BenQ Medical Technology Return-on-Tangible-Asset Related Terms
BenQ Medical Technology Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for BenQ Medical Technology's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BenQ Medical Technology Return-on-Tangible-Asset Chart
ROCO:4116 vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, BenQ Medical Technology's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BenQ Medical Technology Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BenQ Medical Technology's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where BenQ Medical Technology's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 0.99% mean?
BenQ Medical Technology (ROCO:4116) has a Return-on-Tangible-Asset of 0.99% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BenQ Medical Technology and its competitors. This is 71% below median its historical median of 3.41. Over the past decade, BenQ Medical Technology's Return-on-Tangible-Asset has ranged from 1.38 to 5.80. According to the industry distribution chart, BenQ Medical Technology ranks #413 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 48.3%.
Is BenQ Medical Technology's Return-on-Tangible-Asset too high?
BenQ Medical Technology's current Return-on-Tangible-Asset of 0.99% is 71% below median its 10-year median of 3.41. Over the past 10 years, this metric has ranged from a low of 1.38 to a high of 5.80. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.89. BenQ Medical Technology's value of 0.99% is 11.2% above this industry median. Based on the distribution chart, BenQ Medical Technology ranks #413 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, BenQ Medical Technology has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BenQ Medical Technology's Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, BenQ Medical Technology ranks #413 out of 855 companies for Return-on-Tangible-Asset. This puts BenQ Medical Technology in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.89. BenQ Medical Technology's value of 0.99% is 11.2% above this benchmark. Historically, BenQ Medical Technology's own Return-on-Tangible-Asset has ranged from 1.38 to 5.80 over the past decade. While the company's 10-year median is 3.41 vs. the industry median of 0.89, BenQ Medical Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.89, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BenQ Medical Technology's current Return-on-Tangible-Asset of 0.99% is 11.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BenQ Medical Technology and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BenQ Medical Technology's current Return-on-Tangible-Asset is 0.99%, which is 71% below median its own 10-year median of 3.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BenQ Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, BenQ Medical Technology (ROCO:4116) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$58.30, compared to a current price of NT$39.35 — trading 32.5% below its estimated fair value. The current Return-on-Tangible-Asset is 0.99%, which is 71% below median its 10-year median of 3.41 and 11.2% above the Medical Devices & Instruments industry median of 0.89. BenQ Medical Technology's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For BenQ Medical Technology (ROCO:4116), the current Return-on-Tangible-Asset is 0.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BenQ Medical Technology (ROCO:4116) Overvalued in 2026?
Based on GuruFocus' analysis, BenQ Medical Technology stock appears to be undervalued.
The current stock price of NT$39.35 is trading 32.5% below its estimated GF Value™ of NT$58.30.
GuruFocus considers BenQ Medical Technology to be Significantly Undervalued.
Key valuation signals for ROCO:4116:
Return-on-Tangible-Asset: 0.99% (71% below median its 10-year median of 3.41)
GF Value™: NT$58.30 vs. price of NT$39.35 (32.5% below fair value)
Industry Position: 11.2% above the Medical Devices & Instruments median (#413 of 855)
No single metric tells the full story. See the ROCO:4116 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BenQ Medical Technology Corp is engaged in the manufacturing, assembly, maintenance, repair, and sales of professional medical equipment and consumables. Its products include surgical and gynecology tables, digital OR solutions, halogen and LED surgical lights, and medical imaging products, among others. The company's segment includes the R&D and Manufacturing Division and the Medical Services Division. The company generates the majority of its revenue from the Medical Services Division. Geographically, the company generates revenue from Taiwan, Mainland China, Indonesia, Thai, India, Colombia, and Others.
80GF Score
Get the complete analysis for ROCO:4116
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4116 has been successfully added to your 
